Proactive Investors - Run By Investors For Investors

Genedrive has Hepatitis C test performance data published in leading medical journal

The paper concluded that Genedrive’s HCV ID Kit was a rapid, simple, portable and accurate near patient molecular test for HCV
Blood samples
The test was validated in a real clinical setting in a resource-limited country

Genedrive PLC (LON:GDR) said analytical performance and field studies of its Hepatitis C (HCV) ID Kit have been published in BMJ Gut, a leading international journal in gastroenterology and hepatology.

The AIM-listed diagnostics company said the publication reports on assay performance data generated and used for its CE-IVD certification, including analytical performance data as well as field performance evaluation.

READ: Genedrive to premiere Hepatitis C test at Asia-Pacific medical exhibition

The paper had concluded that Genedrive’s HCV ID Kit was a rapid, simple, portable and accurate near patient molecular test for HCV, with sensitivity and specificity that fulfils the recent World Health Organization (WHO) target product profile for HCV decentralised testing in low income and middle-income countries.

The group added that pan-genotype performance, with excellent exclusivity for non-HCV pathogens and sensitivity of greater than 98% and specificity of 100% in samples of European and African origin (including South Africa, Kenya, Ghana, Nigeria, Uganda), was observed and that the test was validated in a real clinical setting in a resource-limited country.

David Budd, Genedrive chief executive, commented: "This high impact peer reviewed publication provides further validation of the performance of our Genedrive HCV ID assay.

He added: “We are first to market with a decentralised qualitative molecular HCV test for use at point of need and believe we have the potential to positively impact the continuum of care from screening to cure by supporting real-time treatment decisions."

Genedrive shares were steady in mid-morning trading Tuesday at 38.5p.

--Adds share price--

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
bacteria
December 17 2018
Summit has big plans for its flagship ridinilazole C. Diff treatment as well as its gonorrhoea and hospital superbug candidates this year, and it now has the funds to develop all of them as intended
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use